Yanruide (Charlie) is currently working in Dr. Lili Yang Lab and is studying iNKT cell based cancer immunotherapy. He is developing hematopoietic stem cell-engineered iNKT cell (HSC-iNKT) adoptive therapy, which aims to provide patients with a life-long supply of potent cancer-targeting iNKT cells.
Hematopoietic stem cell-engineered invariant natural killer T cells for cancer immunotherapy – Yanni Zhu, Drake J. Smith, Yang Zhou, Yan-Ruide Li, Jiaji Yu et al. Cell Stem Cell. 2019, 3;25(4):542-557.
Generation of allogeneic hematopoietic stem cell-engineered invariant natural killer T cells for off-the-shelf immunotherapy – Yan-Ruide Li, Yang Zhou, Yu Jeong Kim et al. (Submit to Cell Stem Cell).
Hematopoietic stem cell-engineered invariant natural killer T cells for allogeneic Graft-Versus-Host disease prevention – Yan-Ruide Li, Samuel Zeng, Yang Zhou et al. (In Preparation)
A Next-Generation, Off-The-Shelf Hematopoietic Stem Cell-based CAR-iNKT Cell Therapy for Cancer -Yu Jeong Kim, Jiaji Yu, Yan-Ruide Li, Zhe Li et al. (In Preparation)
Off-the-shelf Hematopoietic Stem Cell-based NY-ESO-1-specific T cells for Immunotherapy – Jiaji Yu, Yu Jeong Kim, Yan-Ruide Li, Yu-Chen Wang et al. (In Preparation)